Clinical Trial Update: The Beta Cell Responsiveness to Glucose-dependent Insulinotropic Polypeptide (GIP) With and Without Sulfonylurea in Patients With Type 2 Diabetes [Phase 2]

View source ↗

Summary

A Phase 2 study assessed beta-cell responsiveness to glucose-dependent insulinotropic polypeptide (GIP) with and without a sulfonylurea in patients with Type 2 …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• GIP (glucose-dependent insulinotropic polypeptide) (glucose-dependent insulinotropic polypeptide)
• Sulfonylurea (class)

Snippet

Sponsor: University Hospital, Gentofte, Copenhagen | Conditions: Diabetes Mellitus, Type 2 | Phase 2 | Status: COMPLETED | Results posted: 2008-10-02